ACP
SRPT icon

Acuta Capital Partners’s Sarepta Therapeutics SRPT Stock Holding History

Acuta Capital Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-50,000
Closed -$1.37M – 74
2016
Q4 		$1.37M Buy
+50,000
New +$2.01M 0.51% 31

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Acuta Capital Partners's SRPT Position: Q3 2024 in Review

Acuta Capital Partners sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 27,500 shares — an estimated $4.34M sold.

Acuta Capital Partners first reported a position in SRPT in Q3 2015 and held it in 11 quarters. The position peaked at $8.75M in Q4 2022. 458 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Acuta Capital Partners reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 27,500 Sarepta Therapeutics shares in Q3 2024, an estimated $4.34M.
  • Acuta Capital Partners first reported a position in Sarepta Therapeutics in Q3 2015 and held it in 11 quarters.
  • Acuta Capital Partners's Sarepta Therapeutics position peaked at $8.75M in Q4 2022.
  • 458 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Acuta Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.